Mutated EGFR-IN-2 |
カタログ番号GC36667 |
変異EGFR-IN-2(化合物91)は、特許WO2017036263A1から抽出された変異選択的EGFR阻害剤であり、単一変異EGFR(T790M)および二重変異EGFR(L858R/T790M(IC50=<1nM)およびex19delを含む)を強力に阻害します/T790M)、単一の機能獲得変異体 EGFR (L858R および ex19del を含む) の活性も抑制することができます。変異した EGFR-IN-2 は、抗腫瘍性を示します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2050906-97-1
Sample solution is provided at 25 µL, 10mM.
Mutated EGFR-IN-2 (compound 91) is a mutant-selective EGFR inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC50=<1nM) and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. Mutated EGFR-IN-2 shows anti-tumor antivity[1]. EGFRT790M EGFRL858R EGFRex19del EGFR (L858R/T790M)|<1 nM (IC50)|EGFR (ex19del/T790M)
[1]. 2, 4-di-(nitrogen containing group) substituted pyrimidine compound and preparation method and use thereof.
Average Rating: 5
(Based on Reviews and 40 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *